Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Physostigmine [USP:BAN]
RN: 57-47-6
UNII: 9U1VM840SP
InChIKey: PIJVFDBKTWXHHD-HIFRSBDPSA-N

Note

  • A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

Molecular Formula

  • C15-H21-N3-O2

Molecular Weight

  • 275.35
 

Classification Codes

Classification Codes

  • Autonomic Agents
  • Cholinergic (Ophthalmic)
  • Cholinergic Agents
  • Cholinesterase Inhibitors
  • Drug / Therapeutic Agent
  • Enzyme Inhibitors
  • Human Data
  • Miotics
  • Natural Product
  • Neurotransmitter Agents
  • Peripheral Nervous System Agents
  • Reproductive Effect

Superlist Classification Code

  • Threshold Planning Quantity (TPQ) = 100/10000 lb
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Regulatory Agencies (Superlist Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Physostigmine
  • Physostigmine [USP:BAN]

MeSH Heading

  • Physostigmine

Synonyms

  • (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol methylcarbamate (ester)
  • 1,2,3,3abeta,8abeta-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)-indol-5-yl methylcarbamate
  • Antilirium
  • Calabarine
  • Carbamic acid, methyl-, ester with eseroline
  • CCRIS 3422
  • CS 58525
  • EINECS 200-332-8
  • Eserine
  • Eserolein, methylcarbamate (ester)
  • Esromiotin
  • Ezerin
  • Fysostigmin
  • Fysostigmin [Czech]
  • HSDB 3161
  • MCV 4484
  • Methyl-carbamic acid, ester with eseroline
  • NIH 10421
  • NSC 30782
  • Physostigmine
  • Physostol
  • Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)
  • Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-
  • UNII-9U1VM840SP

Systematic Names

  • Physostigmine
  • Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)-
  • Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-

Superlist Names

  • Physostigmine
  • Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-
  • RCRA waste no. P204

Registry Numbers

CAS Registry Number

  • 57-47-6

FDA UNII

  • 9U1VM840SP

Other Registry Numbers

  • 50975-37-6
  • 511-49-9

System Generated Number

  • 0000057476

Structure Descriptors

InChI

InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1

InChIKey

PIJVFDBKTWXHHD-HIFRSBDPSA-N

Smiles

CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LD50 intravenous 660ug/kg (0.66mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 88, Pg. 39, 1946.
dog LDLo subcutaneous 1138ug/kg (1.138mg/kg) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

GASTROINTESTINAL: ULCERATION OR BLEEDING FROM LARGE INTESTINE		 Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 5, Pg. 184, 1946.
human TDLo oral 20mg/kg (20mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: COMA		 "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 475, 1969.
mammal (species unspecified) LD50 unreported 600ug/kg (0.6mg/kg)   United States Patent Document. Vol. #5409948,
man LDLo unreported 882ug/kg (0.882mg/kg)   "Poisoning; Toxicology, Symptoms, Treatments," 2nd ed., Arena, J.M., Springfield, IL, C.C. Thomas, 1970Vol. 2, Pg. 73, 1970.
man TDLo oral 12mg/kg/60D-I (12mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) Neurology. Vol. 37, Pg. 345, 1987.
mouse LD50 intramuscular 330ug/kg (0.33mg/kg)   Journal of Medicinal Chemistry. Vol. 33, Pg. 577, 1990.
mouse LD50 intraperitoneal 644ug/kg (0.644mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

LUNGS, THORAX, OR RESPIRATION: CYANOSIS

LUNGS, THORAX, OR RESPIRATION: DYSPNEA		 Farmakologiya i Toksikologiya Vol. 43, Pg. 717, 1980.
mouse LD50 intravenous 400ug/kg (0.4mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 58, Pg. 337, 1936.
mouse LD50 oral 3mg/kg (3mg/kg)   "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 452, 1948.
mouse LD50 parenteral 600ug/kg (0.6mg/kg)   United States Patent Document. Vol. #5306825,
mouse LD50 subcutaneous 740ug/kg (0.74mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)		 Journal of Pharmacology and Experimental Therapeutics. Vol. 123, Pg. 121, 1958.
pigeon LDLo subcutaneous 450ug/kg (0.45mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
rabbit LD50 intramuscular 2200ug/kg (2.2mg/kg)   Drug and Chemical Toxicology. Vol. 3, Pg. 319, 1980.
rabbit LD50 intraperitoneal 2470ug/kg (2.47mg/kg)   Archives Belges de Medecine Sociale, Hygiene, Medecine du Trevail et Medecine Legale. Vol. (Suppl), Pg. 226, 1984.
rabbit LD50 intravenous 500ug/kg (0.5mg/kg)   "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 452, 1948.
rabbit LD50 oral 11200ug/kg (11.2mg/kg)   Drug and Chemical Toxicology. Vol. 3, Pg. 319, 1980.
rabbit LD50 subcutaneous 3mg/kg (3mg/kg)   "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 452, 1948.
rat LD50 intraperitoneal 2mg/kg (2mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 1926, 1972.
rat LD50 oral 4500ug/kg (4.5mg/kg)   United States Patent Document. Vol. #5302593,
rat LDLo subcutaneous 1mg/kg (1mg/kg)   United States Patent Document. Vol. #5318967,
women TDLo oral 40ug/kg/5D-I (0.04mg/kg) VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION American Journal of Psychiatry. Vol. 143, Pg. 910, 1985.
women TDLo oral 3920ug/kg/2W- (3.92mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) Neurology. Vol. 37, Pg. 345, 1987.

Physical Properties

Physical Property Value Units Temp (deg C) Source
Melting Point 105.5 deg C   EXP
pKa Dissociation Constant 6.12 (none)   EXP
log P (octanol-water) 1.58 (none)   EXP
Water Solubility 7760 mg/L 25 EST
Vapor Pressure 3.66E-06 mm Hg 25 EST
Henry's Law Constant 3.03E-11 atm-m3/mole 25 EST
Atmospheric OH Rate Constant 2.94E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.